Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1551 to 1600 of 3765 results for treatment

  1. Bile acid malabsorption: colesevelam (ESUOM22)

    Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

    Evidence summary
    Published
    29 October 2013

  2. Management of stable angina in people with evidence of ischaemia on non-invasive functional testing:- Do people with stable angina and evidence of reversible ischaemia on noninvasive functional testing who are on optimal drug treatment benefit from routine coronary angiography with a view to revascularisation?

    reversible ischaemia on noninvasive functional testing who are on optimal drug treatment benefit from routine coronary angiography with...

    Research recommendation
    Published
    9 June 2015

  3. Herbal medicines:- Are Chinese and non-Chinese herbal medicines safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most effective and safe option?

    non-Chinese herbal medicines safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is...

    Research recommendation
    Published
    9 June 2015

  4. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

    NICE guideline
    Published
    14 January 2025

    Sections for NG246

  5. Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with lymphoma:- Randomised studies should investigate primary prophylaxis of neutropenic sepsis in 2 populations: children and young people (aged under 18) having treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with lymphoma. The studies should compare the effectiveness of fluoroquinolone antibiotics given alone, fluoroquinolone antibiotics given together with G-CSF preparations, and G-CSF preparations given alone. Outcome measures should include overall mortality, infectious episodes and adverse events. In addition, quality of life should be determined using quantitative and qualitative methods. The resulting data should be used to develop a cost-effectiveness analysis comparing these 3 forms of prophylaxis in children and young people having anticancer treatment, and in adults diagnosed with lymphoma.

    CG151/4 Question Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with...

    Research recommendation
    Published
    9 June 2015

  6. Algorithms applied to spirometry to support the diagnosis of lung conditions in primary care and community diagnostic centres

    In development Reference number: GID-HTE10065 Expected publication date:  02 April 2026

    Health technology evaluations
    In development

  7. Information for family members or carers: What information and support are needed by family members or carers of people having treatment with an opioid, benzodiazepine, Z‑drug, antidepressant or gabapentinoid?

    information and support are needed by family members or carers of people having treatment with an opioid, benzodiazepine, Z‑drug,...

    Research recommendation
    Published
    11 May 2022

  8. Fetal alcohol spectrum disorder (QS204)

    This quality standard covers assessing and diagnosing fetal alcohol spectrum disorder (FASD) in children and young people. It also covers support during pregnancy to prevent FASD. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    16 March 2022
    View quality statements

    Sections for QS204

  9. Which interventions for other communicable diseases could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment?

    risk of hepatitis B and C infection to take up the offer of testing and treatment? Any explanatory notes(if applicable) None. Source...

    Research recommendation
    Published
    9 June 2015

  10. Abortion care (NG140)

    This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.

    NICE guideline
    Last updated
    27 May 2025
    View recommendations

    Sections for NG140

  11. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges (NG11)

    This guideline covers interventions and support for children, young people and adults with a learning disability and behaviour that challenges. It highlights the importance of understanding the cause of behaviour that challenges, and performing thorough assessments so that steps can be taken to help people change their behaviour and improve their quality of life. The guideline also covers support and intervention for family members or carers.

    NICE guideline
    Published
    29 May 2015
    View recommendations

    Sections for NG11

  12. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (HTG724)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

    HealthTech guidance
    Published
    31 July 2024
    View recommendations

    Sections for HTG724

  13. SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (HTG598)

    Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea.

    HealthTech guidance
    Published
    17 November 2021
    View recommendations

    Sections for HTG598

  14. NICE real-world evidence framework (ECD9)

    This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  15. Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem cell transplantation compared with autologous stem cell transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first relapse?

    autologous stem cell transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first...

    Research recommendation
    Published
    5 April 2016

  16. moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (HTG257)

    Evidence-based recommendations on moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment.

    HealthTech guidance
    Last updated
    7 August 2017
    View recommendations

    Sections for HTG257

  17. What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?

    NG191/3 Question What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a...

    Research recommendation
    Published
    10 August 2021

  18. Acute hepatic encephalopathy:- In people with cirrhosis and an acute episode of hepatic encephalopathy secondary to a clearly identified, potentially reversible precipitating factor, does management of the precipitating event alone improve the hepatic encephalopathy without specific treatment?

    precipitating event alone improve the hepatic encephalopathy without specific treatment? Any explanatory notes(if applicable) Why this...

    Research recommendation
    Published
    11 January 2024

  19. What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with chemotherapy-induced nausea and vomiting which persists with optimised conventional antiemetics?

    and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with chemotherapy-induced nausea and...

    Research recommendation
    Published
    10 February 2020

  20. End of life care for adults (QS13)

    This quality standard covers care for adults (aged 18 and over) who are approaching the end of their life. This includes people who are likely to die within 12 months, people with advanced, progressive, incurable conditions and people with life-threatening acute conditions. It also covers support for their families and carers. It includes care provided by health and social care staff in all settings. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    2 September 2021
    View quality statements

    Sections for QS13

  21. Bipolar disorder in adults (QS95)

    This quality standard covers recognising, assessing and managing bipolar disorder in adults (aged 18 and over) in primary and secondary care. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    18 February 2016
    View quality statements

    Sections for QS95

  22. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention as reported by the IMPACT trial, but delivered by practitioners other than psychiatrists and in other settings, including primary care, to young people aged 12 to 18 years with mild or moderate to severe depression?

    Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention...

    Research recommendation
    Published
    25 October 2019

  23. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  24. Organisational models for AMD diagnosis and management:- What is the long-term effectiveness, in terms of patient-relevant outcomes including visual acuityand quality of life, of different models of care that aim to reduce time from initial presentation to referral, diagnosis and treatment?

    aim to reduce time from initial presentation to referral, diagnosis and treatment? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    13 November 2018

  25. NICE encourages further research on transcranial magnetic stimulation (TMS) for treating and preventing migraine. Data should be collected for all patients not entered into controlled trials. Studies should describe clearly whether its use is for treatment or prevention. They should report details of patient selection and the dose and frequency of use. Outcome measures should include the number and severity of migraine episodes, and quality of life in both the short and long term. The development of any neurological disorders (such as epilepsy) in the short or longer term after starting treatment should be documented.

    controlled trials. Studies should describe clearly whether its use is for treatment or prevention. They should report details of patient...

    Research recommendation
    Published
    9 June 2015

  26. For people who have experienced suspected anaphylaxis, what is the effect on health-related quality of life of (a) referral to specialist allergy services and (b) provision of adrenaline injectors, when compared with emergency treatment alone?

    and (b) provision of adrenaline injectors, when compared with emergency treatment alone? Any explanatory notes(if applicable) Why this...

    Research recommendation
    Published
    26 October 2020

  27. NICE encourages further research and data collection on partial replacement of the meniscus of the knee using a biodegradable scaffold. This should include clear descriptions of patient selection and adjunctive treatments. Outcome measures should include symptom relief and functional ability in the short term and the need for further treatment in the longer term.

    adjunctive treatments. Outcome measures should include symptom relief and functional ability in the short term and the need for further...

    Research recommendation
    Published
    9 June 2015

  28. Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment (HTG665)

    Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.

    HealthTech guidance
    Last updated
    10 August 2023
    View recommendations

    Sections for HTG665

  29. Gynaecological conditions: rates of hysterectomy (heavy menstrual bleeding) (IND58)

    This indicator covers rates of hysterectomy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG77

    Network / system level indicators
    Last updated
    22 March 2024

  30. Epilepsy: register (IND253)

    This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over receiving drug treatment for epilepsy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM237

    General practice indicators suitable for use in QOF
    Published
    19 August 2023

  31. Investigations for proteinuria: What is the effect of measuring proteinuria with albumin:creatinine ratio compared with protein:creatinine ratio on the timing of treatment changes in children and young people with CKD? [2021]

    albumin:creatinine ratio compared with protein:creatinine ratio on the timing of treatment changes in children and young people with...

    Research recommendation
    Published
    30 September 2021

  32. AposHealth for knee osteoarthritis (HTG671)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

    HealthTech guidance
    Published
    11 April 2023
    View recommendations

    Sections for HTG671

  33. Head injury: assessment and early management (NG232)

    This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

    NICE guideline
    Published
    18 May 2023
    View recommendations

    Sections for NG232

  34. Optilume for treating recurrent bulbar urethral strictures (HTG649)

    Evidence-based recommendations on Optilume for treating recurrent bulbar urethral strictures.

    HealthTech guidance
    Published
    29 November 2022
    View recommendations

    Sections for HTG649

  35. Radiofrequency ablation for colorectal liver metastases (IPG327)

    Evidence-based recommendations on radiofrequency ablation for the treatment of colorectal liver metastases. This involves using heat to destroy cancer cells in the liver.

    Interventional procedures guidance
    Published
    16 December 2009
    View recommendations

    Sections for IPG327

  36. Compression products for treating venous leg ulcers: late-stage assessment (HTG758)

    Late-stage assessment (LSA) guidance on compression products for treating venous leg ulcers.

    HealthTech guidance
    Published
    27 August 2025
    View recommendations

    Sections for HTG758

  37. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (HTG386)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).

    HealthTech guidance
    Published
    7 October 2015

    Sections for HTG386

  38. Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118)

    This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.

    Clinical guideline
    Last updated
    20 September 2022
    View recommendations

    Sections for CG118

  39. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued Reference number: GID-TA11239

    Technology appraisal guidance
    Discontinued

  40. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued Reference number: GID-TA11258

    Technology appraisal guidance
    Discontinued

  41. Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (TA1034)

    Evidence-based recommendations on anhydrous sodium thiosulfate (Pedmarqsi) for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours.

    Technology appraisal guidance
    Published
    22 January 2025

    Sections for TA1034

  42. Current evidence on the safety and efficacy of radially emitting laser fibre treatment of an anal fistula is limited in quantity and quality. Therefore, although there are no major safety concerns, this procedure should only be used with special arrangements  for clinical governance, consent, and audit or research.

    Current evidence on the safety and efficacy of radially emitting laser fibre treatment of an anal fistula is limited in quantity and...

    Research recommendation
    Published
    15 November 2019

  43. GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

    HealthTech guidance
    Published
    3 April 2024
    View recommendations

    Sections for HTG716

  44. Mental health of adults in contact with the criminal justice system (QS163)

    This quality standard covers recognising, assessing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system (this includes police contact, court and prison custody, street triage, liaison and diversion services, and probation services). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    9 February 2018
    View quality statements

    Sections for QS163

  45. Self-monitoring strategies:- Does earlier detection of the incidence of late AMD (wet active) by self-monitoring in people diagnosed with early AMD, indeterminate AMD or late AMD (dry) lead to earlier treatment and better long-term outcomes?

    people diagnosed with early AMD, indeterminate AMD or late AMD (dry) lead to earlier treatment and better long-term outcomes? Any...

    Research recommendation
    Published
    13 November 2018

  46. Monitoring adherence to treatment:- What is the clinical and cost effectiveness of using electronic alert systems designed to monitor and improve adherence with regular inhaled maintenance therapy in people with asthma?

    Recommendation ID NG80/3 Question Monitoring adherence to treatment:- What is the clinical and cost effectiveness of using electronic...

    Research recommendation
    Published
    18 October 2018

  47. Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management

    In development Reference number: GID-NG10435 Expected publication date: TBC

    NICE guideline
    In development

  48. Interim process and methods statement for bringing together NICE guidance (PMG47)

    This interim process and methods statement sets out the general principles guiding NICE's approach to including NICE technology appraisal recommendations in guideline topic areas. It also describes what the key changes are to existing methods and processes

  49. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

    HealthTech guidance
    Published
    26 September 2023
    View recommendations

    Sections for HTG694

  50. Forward view - our priority topics

    Our forward view highlights the topics we will prioritise in the coming year.